Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Casali (Pavia, Italy). Atypical mycobacteriosis : new drugs, new strategies. Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease

Member's Comments

No comment yet.

Related content which might interest you: The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Treating sarcoidosis and potential new drugs Source: Eur Respir Monogr 2022; 96: 328-336 Year: 2022 Bronchiectasis: new therapies and perspectives Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment Year: 2018 Novel NTM treatments and approaches, repurposed to bacteriophages Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment Year: 2021 Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Collapse therapy using endobronchial valves as a new approach to treat cavities in MDR tuberculosis and selected cases of mycobacteriosis: Case series report Source: International Congress 2015 – Advances in therapeutic bronchoscopy Year: 2015 Novel drugs against tuberculosis: a clinician's perspective Source: Eur Respir J 2015; 45: 1119-1131 Year: 2015 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Rare pulmonary disease and orphan drugs: a path to the future Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019 Year: 2019 HAP/VAP : new guidelines, new approaches Source: International Congress 2018 – Chinese Programme 2018: Part II Year: 2018 From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections Source: International Congress 2017 – Scientific year in review Year: 2017 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014